Biovest International, a majority-owned subsidiary of Accentia Biopharmaceuticals, has executed a distribution agreement with Idis, a European drug distributor, to exclusively supply BiovaxID, a personalized, anti-idiotype cancer vaccine, under a named-patient program in France, Germany, Italy, Greece, Spain and the UK.

Biovest, a subsidiary of Accentia, has announced positive data from a pivotal trial of BiovaxID in lymphoma, and the vaccine now stands a good chance of becoming the first therapeutic cancer vaccine to gain approval in the seven major markets.

Biovest International, Inc. (OTCBB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), today announced that its Chairman and CEO, Dr.

The following letter is from Dr. Steven Arikian, Chairman and Chief Executive Officer of Biovest International, Inc. (OTCBB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI).